Stockreport

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Inc.  (EPRX) 
PDF Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, [Read more]